Literature DB >> 11991994

Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.

Liqun Zhang1, Mark E Peeples, Richard C Boucher, Peter L Collins, Raymond J Pickles.   

Abstract

Gene therapy for cystic fibrosis (CF) lung disease requires efficient gene transfer to airway epithelial cells after intralumenal delivery. Most gene transfer vectors so far tested have not provided the efficiency required. Although human respiratory syncytial virus (RSV), a common respiratory virus, is known to infect the respiratory epithelium, the mechanism of infection and the epithelial cell type targeted by RSV have not been determined. We have utilized human primary airway epithelial cell cultures that generate a well-differentiated pseudostratified mucociliary epithelium to investigate whether RSV infects airway epithelium via the lumenal (apical) surface. A recombinant RSV expressing green fluorescent protein (rgRSV) infected epithelial cell cultures with high gene transfer efficiency when applied to the apical surface but not after basolateral inoculation. Analyses of the cell types infected by RSV revealed that lumenal columnar cells, specifically ciliated epithelial cells, were targeted by RSV and that cultures became susceptible to infection as they differentiated into a ciliated phenotype. In addition to infection of ciliated cells via the apical membrane, RSV was shed exclusively from the apical surface and spread to neighboring ciliated cells by the motion of the cilial beat. Gross histological examination of cultures infected with RSV revealed no evidence of obvious cytopathology, suggesting that RSV infection in the absence of an immune response can be tolerated for >3 months. Therefore, rgRSV efficiently transduced the airway epithelium via the lumenal surface and specifically targeted ciliated airway epithelial cells. Since rgRSV appears to breach the lumenal barriers encountered by other gene transfer vectors in the airway, this virus may be a good candidate for the development of a gene transfer vector for CF lung disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991994      PMCID: PMC137037          DOI: 10.1128/jvi.76.11.5654-5666.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Respiratory syncytial virus and parainfluenza virus.

Authors:  C B Hall
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

2.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Ribavirin for treatment of RSV infection.

Authors:  J M Rimar
Journal:  MCN Am J Matern Child Nurs       Date:  1986 Nov-Dec       Impact factor: 1.412

4.  Kinetics of the respiratory syncytial virus growth cycle in HeLa cells.

Authors:  S Levine; R Hamilton
Journal:  Arch Gesamte Virusforsch       Date:  1969

Review 5.  Disturbances of the ciliated epithelium due to influenza virus.

Authors:  J F Hers
Journal:  Am Rev Respir Dis       Date:  1966-03

6.  Proliferation of respiratory tract epithelium in the rat.

Authors:  W K Blenkinsopp
Journal:  Exp Cell Res       Date:  1967-04       Impact factor: 3.905

7.  Demonstration of respiratory syncytial virus in an autopsy series.

Authors:  K A Neilson; E J Yunis
Journal:  Pediatr Pathol       Date:  1990

8.  Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome.

Authors:  G Delage; P Brochu; L Robillard; G Jasmin; J H Joncas; N Lapointe
Journal:  Arch Pathol Lab Med       Date:  1984-08       Impact factor: 5.534

9.  Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; V G Hemming; R L Horswood; P A Baron; R M Chanock
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Effects of ribavirin on respiratory syncytial virus in vitro.

Authors:  J F Hruska; J M Bernstein; R G Douglas; C B Hall
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  271 in total

1.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors:  Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 5.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

6.  Infection and propagation of human rhinovirus C in human airway epithelial cells.

Authors:  Weidong Hao; Katie Bernard; Nita Patel; Nancy Ulbrandt; Hui Feng; Catherine Svabek; Susan Wilson; Christina Stracener; Kathy Wang; Joann Suzich; Wade Blair; Qing Zhu
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

7.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 8.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Inhibition of Na+ transport in lung epithelial cells by respiratory syncytial virus infection.

Authors:  Lan Chen; Weifeng Song; Ian C Davis; Kedar Shrestha; Erik Schwiebert; Wayne M Sullender; Sadis Matalon
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-23       Impact factor: 6.914

10.  Disruption of the airway epithelial barrier in a murine model of respiratory syncytial virus infection.

Authors:  Carrie C Smallcombe; Debra T Linfield; Terri J Harford; Vladimir Bokun; Andrei I Ivanov; Giovanni Piedimonte; Fariba Rezaee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-29       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.